Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
|
|
Arbutus Biopharma Corp (ABUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/24/2022 |
8-K
| Investor presentation|
Docs:
|
"Arbutus Announces 2022 Corporate Objectives and Provides Financial Update Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161, for the treatment of HBV Advance an nsp5 main protease inhibitor candidate into IND-enabling studies for treatment of SARS-CoV-2 Financial position significantly strengthened; cash runway into Q2 2024 WARMINSTER, Pa., Jan. 24, 2022 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today ...",
"Corporate Presentation January 24, 2022" |
|
| 01/25/2021 |
8-K
| Investor presentation|
Docs:
|
"Arbutus Announces 2021 Corporate Objectives and Provides Financial Update 2021 objectives leverage positive momentum in Arbutus’ Hepatitis B research and development programs WARMINSTER, Pa., Jan. 25, 2021 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses , today announced its 2021 corporate objectives and provided a financial update. William Collier, President and CEO, stated, “We begin 2021 on solid footing from both a pipeline and financial perspective. Our lead clinical asset, AB-729, continues to demonstrate positive data in an ongoing Phase 1a/b clinical trial and we look forward to initiating several Phase 2a clinical tri...",
"Corporate Presentation dated January 2021" |
|
| 01/27/2015 |
8-K
| Investor presentation |
|
|